Difficulty: Medium
Average Score: 87%
Practice
Which of the following mood stabilizers would be most appropriate in a patient with liver disease?
Correct answer
A
Rationale
In a patient with liver disease, the most appropriate mood stabilizer would be lithium (Option A). Lithium is primarily excreted unchanged by the kidneys, making it the safest option in patients with liver impairment as it does not undergo hepatic metabolism. This reduces the risk of drug-induced liver injury or exacerbation of existing liver disease.
Valproic acid (Option B) and carbamazepine (Option C) are metabolized in the liver and can potentially worsen liver function or cause hepatotoxicity in patients with liver disease. Valproic acid, in particular, is known for its hepatotoxic effects and is contraindicated in patients with significant hepatic impairment.
Choosing "None of the above" (Option D) is incorrect because lithium, as mentioned earlier, is the preferred mood stabilizer in patients with liver disease due to its renal excretion pathway.
In an educational context, understanding the pharmacokinetic profiles of different mood stabilizers is crucial in selecting the most appropriate medication for patients with specific comorbidities. It highlights the importance of individualizing treatment plans based on a patient's medical history to minimize the risk of adverse effects and optimize therapeutic outcomes.
Valproic acid (Option B) and carbamazepine (Option C) are metabolized in the liver and can potentially worsen liver function or cause hepatotoxicity in patients with liver disease. Valproic acid, in particular, is known for its hepatotoxic effects and is contraindicated in patients with significant hepatic impairment.
Choosing "None of the above" (Option D) is incorrect because lithium, as mentioned earlier, is the preferred mood stabilizer in patients with liver disease due to its renal excretion pathway.
In an educational context, understanding the pharmacokinetic profiles of different mood stabilizers is crucial in selecting the most appropriate medication for patients with specific comorbidities. It highlights the importance of individualizing treatment plans based on a patient's medical history to minimize the risk of adverse effects and optimize therapeutic outcomes.